Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

A recent meta-analysis shows that acute toxicities following radiation therapy signal a greater risk for later complications in patients with prostate cancer.

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

GU ASCO annual meeting featured a presentation by Dr. David Benjamin discussing the state of the genitourinary medical oncology workforce in the United States in 2024. There are approximately 13,400 ...

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today ...

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...